Resources
51 Results (showing 11 - 20)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 12/15/2020 (updated 4/3/2024)
Dr. Seale led a discussion on communicating OUD needs in your community, building MOUD practice capacity, and other considerations and lessons learned from his work with individuals in rural communities.
Posted 12/9/2020 (updated 4/3/2024)
Emergency Department initiated buprenorphine. This guide includes an overview, list of protocols, tools, and assessments for providers.
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 7/21/2021 (updated 4/2/2024)
RCORP-TA and federal experts provided updates on the process for obtaining and using a waiver to prescribe buprenorphine for the treatment of opioid use disorder with ample time for questions and answers from participants.
Presenter(s): Dr. Melinda Campopiano & Monica Rousseau, DrPH
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.